MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Simulations Plus Inc

Отворен

СекторЗдравеопазване

19.89 6.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.6

Максимум

20.02

Ключови измерители

By Trading Economics

Приходи

-681K

Продажби

17M

P/E

Средно за сектора

48.528

87.826

EPS

-0.034

Дивидентна доходност

0.48

Марж на печалбата

-3.9

Служители

212

EBITDA

-79M

-74M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+5.26% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.48%

2.26%

Следващи печалби

2.04.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

19M

387M

Предишно отваряне

13.7

Предишно затваряне

19.89

Настроения в новините

By Acuity

50%

50%

173 / 370 Класиране в Healthcare

Simulations Plus Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.01.2026 г., 23:54 ч. UTC

Пазарно говорене

CBA Could Underperform Again in 2026 -- Market Talk

12.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen -- Market Talk

12.01.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Lower on Likely Technical Correction -- Market Talk

12.01.2026 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12.01.2026 г., 21:56 ч. UTC

Пазарно говорене

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

12.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

12.01.2026 г., 21:18 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

12.01.2026 г., 21:18 ч. UTC

Пазарно говорене

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12.01.2026 г., 20:54 ч. UTC

Печалби

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12.01.2026 г., 20:48 ч. UTC

Пазарно говорене

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12.01.2026 г., 20:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12.01.2026 г., 20:18 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12.01.2026 г., 20:18 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12.01.2026 г., 19:39 ч. UTC

Пазарно говорене

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12.01.2026 г., 19:36 ч. UTC

Пазарно говорене

Gold and Silver Set New Records on Fed Probe -- Market Talk

12.01.2026 г., 19:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.01.2026 г., 19:33 ч. UTC

Пазарно говорене

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12.01.2026 г., 19:24 ч. UTC

Придобивния, сливания и поглъщания

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12.01.2026 г., 19:22 ч. UTC

Придобивния, сливания и поглъщания

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12.01.2026 г., 18:21 ч. UTC

Придобивния, сливания и поглъщания

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12.01.2026 г., 18:20 ч. UTC

Придобивния, сливания и поглъщания

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12.01.2026 г., 18:19 ч. UTC

Пазарно говорене

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12.01.2026 г., 18:16 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12.01.2026 г., 18:09 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

12.01.2026 г., 18:09 ч. UTC

Пазарно говорене

Baidu's Outlook Bodes Well For Shares -- Market Talk

12.01.2026 г., 18:01 ч. UTC

Придобивния, сливания и поглъщания

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12.01.2026 г., 18:00 ч. UTC

Пазарно говорене

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Simulations Plus Inc Прогноза

Ценова цел

By TipRanks

5.26% нагоре

12-месечна прогноза

Среден 19 USD  5.26%

Висок 19 USD

Нисък 19 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Simulations Plus Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

2

Купи

3

Задържане

0

Продай

Настроение

By Acuity

173 / 370 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat